Northwest Biotherapeutics, Inc  

(Public, NASDAQ:NWBO)   Watch this stock  
+0.009 (1.99%)
Dec 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.47 - 0.51
52 week 0.32 - 4.66
Open 0.47
Vol / Avg. 983,161.00/1.19M
Mkt cap 61.43M
P/E     -
Div/yield     -
EPS -0.78
Shares 123.69M
Beta 1.75
Inst. own 30%

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -18381.76% -6598.10%
Operating margin -16320.13% -7261.88%
EBITD margin - -7258.65%
Return on average assets -233.17% -180.34%
Return on average equity - -
Employees 12 -
CDP Score - -


4800 Montgomery Ln Ste 800
BETHESDA, MD 20814-3676
United States - Map
+1-240-4979024 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company's lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company's platform technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.

Officers and directors

Linda F. Powers Chairperson of the Board, President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Leslie J. Goldman Senior Vice President - Business Development
Age: 70
Bio & Compensation  - Reuters
Anthony E. Maida Ph.D. Senior Vice President - Clinical Research
Age: 61
Bio & Compensation  - Reuters
Marnix L. Bosch Ph.D Chief Technical Officer
Age: 55
Bio & Compensation  - Reuters
Alton L. Boynton Ph.D. Chief Scientific Officer, Director
Age: 71
Bio & Compensation  - Reuters
Susan B. Bayh Independent Director
Age: 55
Bio & Compensation  - Reuters
Cofer Black Independent Director
Bio & Compensation  - Reuters
Robert A. Farmer Independent Director
Age: 75
Bio & Compensation  - Reuters
Jerry J. Jasinowski Independent Director
Age: 72
Bio & Compensation  - Reuters
Navid Malik Independent Director
Age: 46
Bio & Compensation  - Reuters